Literature DB >> 2092039

Augmentation of mouse natural killer (NK) activity by GM-1/P, a processed form of monosialoganglioside GM-1.

A Giuffrida1, M C Galli, A Gismondi, G Santoni, M Piccoli, G Cavallo, E Tubaro, L Frati, A Santoni.   

Abstract

We describe the immunomodulatory activity of GM-1/P a processed form of GM-1 (monosialoganglioside) extracted from ox brain, purified and physically modified. We examined the effect of in vivo and in vitro treatment of GM-1/P on natural (NK) activity and its ability to induce the production of interleukin-2 (IL-2) in the mouse. In vivo treatment with GM-1/P (1 mg/Kg, i.v., day-1) resulted in a marked increase and in a change of distribution of NK activity, which was associated with lower density Percoll fractions. Marked increase was already observed at 18 hrs and then declined by day 4. In vitro treatment with GM-1/P (2 micrograms/ml) enhanced NK activity of B6 spleen cells, already after 6 hours of incubation, remaining at plateau levels within 18 hours. A role of IL-2 in this enhancement was suggested by the ability of an anti-IL-2 rabbit antiserum to abolish in vitro increased cytotoxicity. The presence of IL-2 in the supernatants of splenocytes from GM-1/P (1mg/Kg, i.v., ,day-1) treated mice stimulated with Con A or Con A plus TPA for 48 hrs was evaluated by proliferation of an IL-2 dependent CTLL cell line. GM-1/P by itself was unable to stimulate IL-2 production; however it markedly increased IL-2 production induced by Con A or Con A plus TPA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2092039     DOI: 10.3109/08923979009019676

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  1 in total

1.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.